Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer
- 1 March 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Urology
- Vol. 13 (2), 117-122
- https://doi.org/10.1097/00042307-200303000-00006
Abstract
The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject. The routine use of adjuvant radiation therapy remains a controversial topic. Recent retrospective matched-pair analyses support its use in appropriately selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these and other data vary. Although the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximately 40 to 10% in patients with either positive margins or extraprostatic extension, its effect on cause-specific mortality is unclear. Two prospective randomized trials with cumulative enrollment of over 1400 patients have examined the role of adjuvant radiation therapy compared with observation following prostatectomy: one trial was a National Cancer Institute-sponsored Intergroup study coordinated by the Southwest Oncology Group, and the other was from the European Organization for Research and Treatment of Cancer. Currently, the Radiation Therapy Oncology Group is conducting a three-arm trial, with broadened stratification criteria as compared with previous trials. This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen deprivation following prostatectomy and also androgen deprivation alone in patients at high risk for disease relapse. In lieu of data from completed randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist and are supported by retrospective data with respect to reducing local and biochemical recurrence rates. However, data demonstrating an overall or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage therapy do not exist.Keywords
This publication has 41 references indexed in Scilit:
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Factors Associated With Initial Therapy for Clinically Localized Prostate Cancer: Prostate Cancer Outcomes StudyJNCI Journal of the National Cancer Institute, 2001
- THE ROLE OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMYUrologic Clinics of North America, 2001
- Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigenInternational Journal of Cancer, 2001
- Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapyInternational Journal of Cancer, 2001
- LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARSJournal of Urology, 2000
- The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S.Cancer, 1998
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant ChemotherapyNew England Journal of Medicine, 1997
- Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based StudyJNCI Journal of the National Cancer Institute, 1996
- The results of radical retropubic prostatectomy and adjuvant therapy for pathologic Stage C prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1996